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Edited by Maurice MontalAbstract Botulinum neurotoxins (BoNT) are the etiological
agents responsible for botulism and are acknowledged terrorist
threat agents. Passive immunotherapy may provide one counter-
measure. Importantly, in the virtually unlimited repertoire of
antibody speciﬁcities, enzyme linked immunosorbent assays
(ELISA) has become an indispensable method for antibody selec-
tion. We report that of the BoNTs, BoNT/E is highly susceptible
to polystyrene induced denaturation. To further dissect this re-
sult and the potential susceptibility of other BoNTs to denatur-
ation we selected a thermal platform, which could be readily
quantiﬁed using surface plasmon resonance (SPR), a primary
rat spinal cord cell-based assay and an animal lethality model.
 2008 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Botulism can be a fatal disease caused by one of seven bot-
ulinum neurotoxins (BoNTs) (distinct antigenic serotypes A–
G), that are produced by Clostridium botulinum [1]. The disease
is characterized by progressive muscle weakness that can result
in complete ﬂaccid paralysis caused by blockage of acetylcho-
line release from nerve terminals at the neuromuscular junc-
tion [2]. All seven BoNTs have a similar structural
organization and are synthesized ﬁrst as a single polypeptide
chain of 150 kDa, which is then proteolytically activated as di-
chain toxin composed of a heavy chain (100 kDa) and a light
chain (50 kDa) covalently linked by at least one disulﬁdeAbbreviations: BoNT(s), botulinum neurotoxin(s); BoNT/A–G, botu-
linum neurotoxin type A–G; BoNT/HcE, heavy chain neuro-speciﬁc
binding domain of botulinum neurotoxin type E; ELISA, enzyme
linked immunosorbent assay; SPR, surface plasmon resonance; mAb,
monoclonal antibody; pAb, polyclonal antibody; RSC, rat spinal cord;
TMepi, midpoint when 50% of an epitope(s) conformation is changed;
TEepi, endpoint when 100% of an epitope(s) conformation is changed
*Corresponding author. Address: Worm Institute for Research and
Medicine (WIRM), The Scripps Research Institute, 10550 North
Torrey Pines Road, La Jolla, CA 92037, USA. Fax: +1 858 784 2595.
E-mail address: kdjanda@scripps.edu (K.D. Janda).
0014-5793/$34.00  2008 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2008.03.047bond [3]. General concerns surrounding the BoNTs are related
to their potency with BoNT/A having a 50% lethal dose (LD50)
by parenteral administration of 0.001 lg/kg [4]. Due to lethal-
ity issues, its ease of production and transport, and the need
for prolonged intensive care among aﬄicted individuals, BoN-
Ts are a real threat to be used as weapons of mass destruction
(WMD) [5,6].
Human botulism is attributed to serotypes A, B and E and
unfortunately there is no known cure for the disorder. Patients
who contract the illness are typically provided with supportive
therapy (ventilator), while prophylactic strategies utilize active
vaccination with BoNT toxoid vaccines [7,8]. Although several
new-generation vaccines are in clinical trials [9–13], passive
immunotherapy still provides an attractive therapeutic
approach against BoNTs intoxication, as it is host-indepen-
dent and can provide a state of immediate immunity and pro-
tection [14]. Many research groups have sought to develop
human protective monoclonal antibody (mAb) against BoNTs
(/A/B/E); yet, no single human mAb has been disclosed that
can eﬀectively prevent BoNT intoxication. However, a recent
in vivo study reported that a series of oligoclonal antibodies
could eﬀectively protect mice against BoNT/A intoxication
[15].
In the process of developing human protective mAbs to
BoNT/A, /B, and /E, and the mapping of their corresponding
epitopes, we discovered an inconsistency in our data, especially
with BoNT/E, wherein our deﬁned mAbs could recognize neu-
rotoxin, heavy chain binding domain (HC), and/or peptide
fragments (derived from HC domain) via an enzyme linked
immunosorbent assays (ELISA) assay; yet these same antibod-
ies were unable to recognize neurotoxin using capture surface
plasmon resonance (SPR). We hypothesized this discrepancy
could be attributed to ELISA as systems that employ immobi-
lization of proteins directly onto a solid plastic surface, suﬀer
from some limitations, the most critical being a physiochemical
tendency of immobilized proteins to undergo conformational
changes and denaturation as a consequence of their binding
to the polystyrene surface. While there is a wealth of data using
ELISA as a means to discover antibodies with varied aﬃnity
and selectivity to BoNTs, there have been no reports of BoNT
denaturation when using ELISA technology. However, several
groups have reported that serum ELISA titers to the BoNTs
do not correspond to neutralizing titers [16,17]. To examine
BoNT stability and to better deﬁne these inconsistent binding
dynamics, we initiated a study using temperature as a thermalblished by Elsevier B.V. All rights reserved.
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and /E. As readouts to address the biological/structural integ-
rity of each neurotoxin, we employed three techniques/assays
including: SPR, a rat spinal cord cell assay, and a mouse
lethality bioassay. Our results indicate that BoNT/E is easily
denatured, either thermal or polystyrene induced, and thus
routine solid-phase-based antibody selection methods are not
readily amenable for deﬁning neutralizing antibodies and/or
epitopes against BoNT/E.2. Materials and methods
2.1. Botulinum neurotoxin, neurotoxin fragments, antibodies and SPR
assays
Pure BoNT types A1, A2, B and E (150 kDa) were prepared from C.
botulinum Hall A hyper, Kyoto A2, Okra B, and Beluga E as previ-
ously described [18,19]. Toxicity of the BoNT/A, /B, and /E prepara-
tions were determined by a standard mouse bioassay (MBA) [20].
Pure BoNT type C, D, F and G were purchased from Metabiologics
Inc. BoNT/E heavy chain neuro-speciﬁc binding domain (HCE, Belu-
ga) was kindly provided by Dr. Joseph T. Barbieri (Medical college
of Wisconsin, Milwaukee, WI, USA), and was prepared in HBS-EP
buﬀer (BR1001-88, Biacore Inc.) at a concentration of 10 lg/mL for
SPR analysis. Toxin solutions (A–G) were individually prepared at a
concentration of 2 lg/mL in HBS-EP buﬀer for all SPR analyses,
cell-based assays and the mouse bioassay. Heat-treated toxin refers
to toxin solution that was incubated at a deﬁned temperature for
30 min with gentle shaking, and then was allowed to cool to the ambi-
ent temperature of 25 C for 1 h. Control toxin refers to a toxin solu-
tion that was prepared and kept at 25 C. The SPR assays were
conducted in triplicate on a Biacore 3000 instrument (Biacore Ab,
Uppsala, Sweden), using HBS-EP buﬀer as a running buﬀer, and all
were double referenced, i.e. with a blank reference ﬂow cell and with
blank buﬀer injections. A positive signal is deﬁned as the SPR response
being equal or greater than 10 standard deviations (10 · SD) of re-
sponse for the control, a buﬀer injection. All ligands were immobilized
onto a Biacore CM5 chip using NHS/EDC coupling chemistry. Mouse
anti-BoNT/E monoclonal antibodies (mAbs) were uncovered and
characterized by routine hybridoma technology using HCE as the anti-
gen. Rabbit anti-BoNT type A, B and E protective polyclonal antibod-
ies (pAbs) were developed and puriﬁed as previously described [21].
2.2. SPR investigations delineating the biophysical interactions of
ELISA deﬁned BoNT/E mAbs and heat-treated BoNT/E
Once a protein is immobilized onto a polystyrene surface, e.g., an
ELISA plate or immunotube, it is diﬃcult to remove it from the solid
surface without undermining its natural 3-dimensional structure. To
address protein denaturation in an alternative well-controlled environ-
ment, we sought the use of temperature. Thus, a solution of BoNT/E
was incubated under various temperatures ranging from 40 C to
90 C, with 10 C intervals and each heat-treated toxin sample was in-
jected into a Biacore 3000 containing a CM5 chip immobilized with
either our previously ELISA deﬁned anti-BoNT/E mAbs or rabbit
anti-BoNT/E pAb (control). Initially native BoNT/E and recombinant
HcE were injected to commence the studies and this was followed by
speciﬁcity analysis with heat-treated BoNT/E and native and heat-trea-
ted BoNTs (A–G, from 40 C to 90 C with intervals of 10 C). We
noted that all samples were injected at a ﬂow rate of 10 lL/min, and
were allowed to bind for 5 min (association phase), followed by wash-
ing for 10 min (dissociation phase). The kinetic constants for mAbs
8F3 and 9E5 to the BoNTs, were determined using the software pro-
vided with the Biacore 3000 and has been described elsewhere [22].
2.3. SPR analysis elucidating the binding interactions of rabbit protective
pAbs with heat-treated BoNTs
To study how rabbit anti-BoNT (/A/B/E) protective pAbs as selected
by ELISA would interact with thermal induced changes to these neu-
rotoxins but now using SPR analysis we immobilized each rabbit anti-
BoNT (/A/B/E) pAb directly onto a CM5 chip (vide supra). BoNT (/A/
B/E) solutions were prepared and an aliquot of each toxin was incu-
bated at a deﬁned temperature for 30 min; the temperatures rangedfrom 37 C to 60 C with 1 C increment and the assay conditions were
identical to that described in Section 2.2. To check the speciﬁcity of
rabbit anti-BoNT (/A/B/E) pAb towards heat-treated toxins, native
and heat-treated BoNTs (A1, A2, B at 54 C and C–G at 50 C) were
injected over a rabbit pAb immobilized chip surface as described in
Section 2.2.
2.4. Validation of the biological activity of heat-denatured BoNT by an
in vitro cell-based assay
To study the inﬂuence of thermal eﬀects on the biological integrity of
the BoNTs (/A/B/E), we employed a primary rat spinal cord (RSC) cell
assay [23]. Here, toxin solution was incubated for 30 min at 49 C and
54 C for BoNT/A and /B and 45 C and 50 C for BoNT/E. The pri-
mary rat spinal cord cells were prepared in 96-well plates [23], and the
cells were exposed to 20, 2, 0.2 and 0.02 ng of heat-treated BoNT (or
native BoNT as control) in a volume of 50 ll, respectively. Each dilu-
tion was tested in triplicate. Cell exposure was for 24 h for BoNT/A
and /E, and 48 h for BoNT/B. Cells were harvested in 75 ll of
1 · LDS buﬀer (Invitrogen), and cell lysates were analyzed by Western
blot as described previously [23].
2.5. Conﬁrmation of the biological activity of heat-denatured BoNT by
in vivo mouse lethality bioassay
To further evaluate the impact of heat treatment on biological activ-
ity of the BoNTs (/A/B/E), we also conducted a standard in vivo mouse
lethality bioassay [20]. In brief, heat-treated BoNTs and control toxin
solution were prepared, as previously described (see Sections 2.1 and
2.4). Pairs of mice (ICR) were injected intraperitoneally with several
dilutions of the toxin as speciﬁed in Table 2, and mice were observed
for signs of botulism for up to 4 days before they were killed.3. Results
3.1. SPR analysis of ELISA selected mAbs and heat-treated
BoNT/E
As shown in Fig. 1, none of the previously selected mAbs, 18
total by ELISA to BoNT/E, could bind to native BoNT/E
using capture SPR, but all mAbs could strongly bind to
HCE; while seven of the mAbs (2A3, 3F11, 8C6, 8F3, 9A11,
9E5, and 16A8) displayed signiﬁcant aﬃnity to heat-treated
BoNT/E (at 50 C), albeit to diﬀerent extents. Finally, any ob-
served binding aﬃnity decreased gradually to a basal level
when the toxin was treated at 60 C or higher.
The outcome of our speciﬁcity analysis using native and
heat-inactivated BoNT serotypes revealed that none of these
seven deﬁned mAbs could bind to the native toxins (A–G),
but they could cross-react with heat-treated BoNT/A2 (at
54 C), /B (at 54 C), and /F (at 50 C), again to diﬀerent
extents; in addition these antibodies were able to bind heat-
treated BoNT/E (at 50 C). Amongst these seven mAbs, only
8F3 could cross-react with heat-treated BoNT/F (50 C),
whereas 9E5 cross-reacted with heat-treated BoNT/A2 (at
54 C). The association/dissociation rate constants and aﬃni-
ties (ka, kd, and KD) for these unique antibodies are summa-
rized in Table 1.
3.2. SPR investigations into the ability of rabbit protective pAbs
to recognize heat-treated BoNTs
The ability of rabbit protective pAbs to bind to BoNTs (/A/
B/E) that have heat induced conformational changes is illus-
trated in Fig. 2. The data demonstrate that the TMepi (midpoint
when 50% of the epitope(s) conformation is changed) was
49 C for BoNT/A and /B, and 45 C for BoNT/E; and TEepi
(endpoint when 100% of the epitope(s) conformation is chan-
ged) occurred at 54 C for BoNT/A and /B, and 50 C for
Fig. 1. Use of capture SPR to determine the relationship between anti-BoNT/E mAbs and thermal induced BoNT/E conformational changes.
Table 1
A list of association/dissociation rate constants and aﬃnities (ka, kd, and KD) as determined for mAb 8F3 and 9E5
mAb Analyte (50 C) ka (M1 s1) kd (s1) KD (M) v2
8F3 BoNT/E 9.76 · 105 1.99 · 107 2.04 · 1013 0.184
8F3 BoNT/F 1.84 · 106 1.43 · 103 7.76 · 1010 0.147
9E5 BoNT/E 2.26 · 105 1.29 · 103 5.72 · 109 0.133
Fig. 2. Relative binding eﬃciency of rabbit anti-BoNT/E pAbs to heat-treated BoNT/A, /B, and /E toxins as detected by capture SPR.
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Fig. 3. Western blots showing the biological activity of heat-treated BoNT/A, /B, and /E toxins as validated in an RSC assay. RSC cells were exposed
to serial dilutions of BoNT/A (a), /B (b), and /E (c), and the cleavage of SNAP 25 (for /A and /E) or VAMP2 (for B) were examined by Western blot
analysis.
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BoNTs serotypes (A–G) illustrated that rabbit anti-BoNT pIg-
Gs only recognized the corresponding native toxin, as no
cross-reactivity was observed with the other native BoNT ser-
otypes and/or with any of the heat-treated BoNTs.
3.3. Investigations into the biological activity of heat-treated
BoNT by an in vitro cell-based assay
How thermal induced changes impact the BoNTs biochem-
ical activity in a RSC assay is shown in Fig. 3. After heat treat-
ment at the determined TEepi, no signiﬁcant target protein
cleavage (SNAP25 for BoNT/A and /E and VAMP2 for
BoNT/B) was observed. In contrast after heat treatment at
the TMepi, some SNAP25 or VAMP2 cleavage was observed
with all toxin dilutions tested; however, at a 2–3–fold lower
eﬃciency than the untreated controls for BoNT/A and /B,
and 1.5–2-fold lower eﬃciency for BoNT/E.
3.4. Conﬁrmation of the biological activity of heat-inactivated
BoNTs by an in vivo mouse bioassay
Findings for the mouse bioassay are summarized in Table 2.
As shown, an LD50 for BoNT/A was determined to be approx-
imately 5 pg. For BoNT/B, the LD50 was found to be less than
5 pg; while for BoNT/E was 20 pg. In our thermal studies an
LD50 for BoNT/A treated at 49 C was estimated to be be-
tween 10 and 20 pg; BoNT/B at 49 C was estimated to be
10 pg, and for BoNT/E treated at 45 C this was established
to be 20 pg. No biological activity was detected with BoNT/Table 2
Validation of the biological activity of heat-treated BoNTs using a
mouse lethality assay





Control 5 4/2 4/4 4/0
10 6/6 6/6 4/0
20 4/4 4/4 4/2
40 4/4 4/4 4/4
49 C (A, B),
or 45 C (E)
10 4/0 4/1 4/0
20 6/6 6/6 4/2
100 4/4 4/4 4/4
500 4/4 4/4 n.t.
54 C (A, B),
50 C (E)
20000 4/0 4/0 4/0A or/B treated at 54 C and BoNT/E treated at 50 C; the lat-
ter was true for BoNTs even when 20 ng of the toxin (P 4000
mouse LD50 for/A and /B or 1000 LD50 for/E) was injected.4. Discussion
There is an impressive body of evidence in the literature
using ELISA to select for neutralizing antibodies to epitopes
of protein antigens. However, ELISA systems may also pose
problems since proteins can denature upon contact with a
polystyrene surface [24,25]. The binding of a protein to a poly-
styrene surface depends on the characteristics of the surface
and on the structure of the protein; binding can induce confor-
mational changes in the adsorbed molecules [26,27]. At the on-
set of our studies we selected 18 anti-BoNT/E mAbs, which
were developed by immunizing mice with the BoNT/HCE frag-
ment. Using this strategy we obtained high titers to HCE and
BoNT/E neurotoxin as judged by ELISA, but these results
were not recapitulated using either ‘‘direct’’-SPR (BoNT/E
immobilized onto a chips surface) or ‘‘capture’’-SPR assays
(mAb immobilized onto a chips surface, unpublished data).
Seeking to solve this quandary, we conducted extensive studies
using SPR technology with deﬁned monoclonal or polyclonal
antibodies and native or thermally denatured BoNTs. The
challenge of delineating polystyrene surface eﬀects and neuro-
toxin toxin inactivation was undertaken using temperature as
opposed to pH or a chemical denaturant as we required a
method that would be common [26,28,29] and need no addi-
tional manipulations before SPR analysis could be conducted
on the sample. In sum, none of the 18 ELISA selected anti-
BoNT/E mAbs had possessed any binding activity to native
BoNT/E in the SPR capture study, Fig. 1.
From the selected pool of mAbs, 7 of the original 18 mAbs
were found to bind to heat-denatured BoNT/E as judged by
‘‘capture’’-SPR with excellent aﬃnity (Table 1) that is consis-
tent with their high titers as seen using the ELISA selection
protocol. Interestingly, antibody speciﬁcity was also broad-
ened to the other serotypes upon heating implying a common
epitope, which might be conformationally linked between the
other serotypes. Montal and co-workers [30] have elegantly
shown while BoNT/A and /E have sequence similarity, their
global structures between these neurotoxins are diﬀerent, espe-
cially at their translocation domain. Translating our ﬁnding to
Montals work suggests that common antibody binding we
have seen between serotypes, which has been introduced ther-
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(HCE). Finally, the 11 mAbs that failed to recognize heat-
denatured holotoxin may recognize epitope(s) that are exposed
in the HCE, but are not readily accessible in native or partially
denatured holotoxin; such as epitope(s) located within or in
close proximity to the hydrophobic patch, where the transloca-
tion domain (HNE) packs tightly with the (HCE) binding do-
main.
To examine additional thermal eﬀects on BoNT/E as well as
BoNT/A and /B, rabbit anti-BoNT/A/B/E pAbs were used as a
probe. The results, Fig. 2, illustrated that the aﬃnity of the
pAbs to the heat-treated BoNTs dropped precipitously at
49 C for BoNT/A/B, and at approximately 45 C for BoNT/
E. Furthermore, a total lack of antibody binding was observed
for BoNT/A/B at 54 C and 50 C for BoNT/E. From these
studies we can conclude that all properly folded conforma-
tional epitopes of the neurotoxins recognized by rabbit pAbs
were ablated by heating at TEepi.
The biological function of a protein is related to its 3-dimen-
sional structure. To deﬁne how thermal eﬀects can impact
BoNTs biological activity at their respective TMepi and TEepi
we investigated two separate but complementary assays the
ﬁrst being a RSC assay (Fig. 3), and the second a mouse lethal-
ity assay (Table 2). Heat treatment of BoNTs at TEepi for
30 min caused at least 1000-fold decrease in toxin activity, sig-
nifying complete or near complete inactivation, whereas heat
treatment of BoNTs at TMepi only slightly reduced toxin activ-
ity (2–3-fold for A and B, and 1.5–2-fold for E), see Fig. 2. In
trying to interpret these results we propose that there is a gen-
eral disruption of accessible epitopes around TMepi, which con-
tributes to the diminished binding seen with the pAbs but not
the overall biochemical activity of the toxin. In contrast upon
reaching the TEepi, disruption of additional epitope(s) appears
catastrophic to both biological activity and pAb antibody
binding.
The results we have presented demonstrated that BoNT/E is
both thermally unstable and highly susceptible to conforma-
tional changes upon adsorption to plastic surfaces. Further-
more, previous mAb binding ELISAs (unpublished data) and
our thermal denaturation studies suggest that BoNT/A, /B
are also susceptible to some form of conformational changes,
but to a lesser extent than BoNT/E. As we have shown when
constructing a strategy for neutralizing antibody selection for
BoNT/E, the pursuant of antibody high titer/aﬃnity as judged
using ELISA could provide false leads of mAbs that recognize
shifted or distinct epitopes. Interestingly, the groups of both
Barbieri and Tekeda have observed that serum ELISA titers
produced to BoNTs heavy chain did not correspond to neu-
tralizing titers, which based on our ﬁndings maybe due to plas-
tic surface denaturation of the BoNTs [16,17]. This is
important as the Barbieri group used the same HCE in their
immunization study and obtained serum that can protect
10,000 LD50 of BoNT/E challenge [16]; this result coupled to
our data would preclude the possibility that the HCE itself is
the culprit limiting our search for neutralizing mAbs. In light
of these facts, the selection of protective antibodies from any
library pool should be predicated upon ways to select directly
against the BoNT in the solution phase. Resolutions to this
problem would include any technique using solution phase,
such as ﬂuorescence sorting [31] or in the case of solid phase
selection, preadsorbed onto an alternative surface such as alu-
minum hydroxide [25], and/or a sandwich capture assay couldbe engaged using non-protective mAbs with distinct epitopes,
preferably located in light chain or the translocation domain.
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